Table 1.
Serum IL-6 levels during COVID-19 in cohort and retrospective studies
| Serum concentration of interleukin-6 (ng/ml) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ref. | Prognostic | Severity | Sex | Whole population | ||||||
| Survival | Death | Asymptomatic | Mild | Moderate | Severe | Critical | M | F | ||
| [130] | – | – | 6.44 (2.34–13.94) | 15.3 (7.70–22.64) | 10.79 (6.93–16.35) | 16.09 (8.08–26.47) | 21.84 (19.88–32.69) | 18.16 (9.16–31.83) | 12.67 (6.93–17.09) | - |
| [49] | 13.3 (3.9–41.1) | 25.2 (9.5–54.5) | ||||||||
| [11] | 6.05 (5.12–6.99) | 10.07 (7.36–14.80) | – | – | – | – |
Without ARDS: 6.29 (5.36–7.83) with ARDS: 7.39 (5.63–10.89) |
– | – | 6.98 (5.46–9.02) |
| [50] | – | – | – | – | – | – | – | – | – | 7.9 (6.1–10.6) |
| [47] | – | – | – | – | – | 15.3 (6.2–29.5) | 41.5 (24.8–114.2) | – | – | 26.6 (7.5–43.4) |
| [51] | – | – | – | – | about 5 | About 12 | about. 15 | – | – | – |
| [59] | from 6.41 (2.17) to 159.2 (268.95) | from 10.96 (5.25) to 2291.46 (568.27) | - | - | - | from 5.0 (3.64) to 51.7 (65.6)) | from 7.4 (3.64) to 103.9 (43.6) | – | – | – |
| [39] | - | - | - | - | 10.4(3.8–31.0) | 5.8 (3.1–16.9) | 64.0 (25.6–111.9) | – | – | – |
| [60] | - | - | - | - | About 100 | – | – | – | ||
| [116] | - | - |
Non severe: 15·67 +/– 6, 34 Severe: 19.0 +/– 7.74 |
- | - | - | ||||
ARDS acute respiratory distress syndrome